Moderna mResvia® – Recommendations & Details
For patients aged 60 or older, the risk of severe RSV infection and hospitalization can be high—making protection by vaccination that much more important.
Respiratory Syncytial Virus (RSV) can cause significant lower respiratory tract disease in older patients, especially those with comorbidities identified by the CDC as heightened risk factors- asthma, diabetes, COPD, CHF, or advanced liver or kidney disease. To protect against RSV, ACIP & CDC recommends vaccinating all adult patients who are aged 75 or older, as well as those who are aged 60 or older that are increased risk of severe RSV disease due to comorbidities or community care setting.
Consider mResvia to protect your elderly population from RSV, the only ACIP-recommended RSV vaccine available in a ready-to-use pre-filled syringe. In clinical trials, mResvia was proven to protect adults aged 60 or older against RSV, regardless of comorbidities or frailty status. Take a look at the resources below for additional information on RSV and mResvia for protection:
mRESVIA Product Information Quick Guide
mRESVIA ACIP Flashcard
mRESVIA Discussion Guide
mResvia should not be administered to individuals with a history of severe allergic reaction (e.g. Anapyhlaxis) to any component of mResvia. In a clinical trial, the most commonly reported (≥10%) adverse reactions were injection-site pain (55.9%), fatigue (30.8%), headache (26.7%), myalgia (25.6%), arthralgia (21.7%), axillary (underarm) swelling or tenderness (15.2%) and chills (11.6%).
To report suspected adverse reactions, contact ModernaTX, Inc. at 1-866-663-3762 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.
